Vimarsana
Biggest News Aggregation in the World

Page 2 - Acting Properties News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acting Properties. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acting Properties Today - Breaking & Trending Today

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022 - Vimarsana News

ViiV Healthcare to present new long-term findings from its innovative 2-drug and long-acting HIV medicines portfolio at CROI 2022

Published: February 7, 2022

Data reinforce ViiV Healthcare's leadership and commitment to developing ground-breaking medicines for HIV treatment and prevention ViiV Healthcare, the global specialist HIV company majority-owned

Source: finanznachrichten.de
Related Topics:
United StatesUnited KingdomNorth CarolinaCity OfUnited Kingdom GeneralKimberly SmithKathleen QuinnDan SmithJosh WilliamsJeff MclaughlinSonya GhobrialMick ReadeyTim FoleyJames DodwellKostenloser WertpapierhandelMelinda StubbeeNick StoneCompany Annual Report On FormPfizer IncShionogi LimitedViiv HealthcareHead Of Research Development At Viiv HealthcareEuropean Medicines AgencyOpportunistic InfectionsResearch Development
GlaxoSmithKline : ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment - Vimarsana News

GlaxoSmithKline : ViiV Healthcare announces US FDA approval of Cabenuva (cabotegravir, rilpivirine) for use every two months, expanding the label of the first and only complete long-acting HIV treatment

Published: February 1, 2022

For media and investors only Issued: London UK Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living... | February 1, 2022

Source: marketscreener.com
Related Topics:
United StatesUnited KingdomSouth AfricaSouth KoreaLynn BaxterTurner OvertonDrug AdministrationJanssen Pharmaceutical Companies Of JohnsonUniversity Of Alabama At BirminghamCompany Annual Report On FormShionogi LimitedPfizer IncViiv Healthcare Patient Assistance ProgramDepartment Of MedicineJanssen Sciences Ireland Unlimited CompanyLondon UnitedViiv HealthcareJanssen Pharmaceutical CompaniesNorth AmericaIntent To Treat ExposedPrimary InvestigatorSafety InformationDrug ReactionSystemic SymptomsInjection Reactions
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment - Vimarsana News

U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment

Published: February 1, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded...

Source: prnewswire.com
Related Topics:
United StatesLos AngelesJames MersonTony MillsJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonSwiss Agency For Therapeutic ProductsAustralia Therapeutic Goods AdministrationMen Health Foundation In Los AngelesJanssen Sciences Ireland Unlimited CompanyDivision Of Janssen ProductsNone Of The Janssen Pharmaceutical CompaniesDrug AdministrationEuropean CommissionExchange CommissionCompanies Of JohnsonHealth CanadaViiv HealthcareCandice LongInfectious DiseasesJanssen TherapeuticsJanssen ProductsGlobal Therapeutic Area HeadJanssen Research
U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment - Vimarsana News

U.S. FDA Approves CABENUVA (rilpivirine and cabotegravir) for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment

Published: February 1, 2022

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded...

Source: prnewswire.com
Related Topics:
United StatesLos AngelesJames MersonTony MillsJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonSwiss Agency For Therapeutic ProductsAustralia Therapeutic Goods AdministrationMen Health Foundation In Los AngelesJanssen Sciences Ireland Unlimited CompanyDivision Of Janssen ProductsNone Of The Janssen Pharmaceutical CompaniesDrug AdministrationEuropean CommissionExchange CommissionCompanies Of JohnsonHealth CanadaViiv HealthcareCandice LongInfectious DiseasesJanssen TherapeuticsJanssen ProductsGlobal Therapeutic Area HeadJanssen Research
ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment - Vimarsana News

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV Treatment

Published: February 1, 2022

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ViiV

Source: finanznachrichten.de
Related Topics:
United StatesNorth CarolinaSouth AfricaCity OfUnited KingdomUnited Kingdom GeneralSouth KoreaLynn BaxterJosh WilliamsJeff MclaughlinMick ReadeyCatherine HartleyLyndsay MeyerTim FoleyMadeleine BreckonEvan BerlandTurner OvertonKathleen QuinnAudrey AbernathyKostenloser WertpapierhandelJames DodwellKristen NeeseNick StoneDrug AdministrationJanssen Pharmaceutical Companies Of Johnson